Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Insights

In this episode, Alison Savas is joined by Pinnacle Investment Management Group’s Chief Investment Strategist, Anthony Doyle.
Antipodes portfolio manager, Nick Cameron, outlines the investment case for US medical device company, Globus Medical.
In this episode of the Good Value podcast, Investment Director, Alison Savas interviews Portfolio Manager, Graham Hay.
Portfolio Manager, Graham Hay and Investment Director, Alison Savas provide a market and portfolio positioning update for Q2 2025.
In this episode of the Good Value podcast, Alison Savas interviews James Rodda, Lead Portfolio Manager of the Antipodes Global SMIDs Fund, to explore why global small and mid-cap stocks (SMIDs) present powerful, under-appreciated alpha opportunities.
Emerging Markets Portfolio Manager, John Stavliotis, provides an overview of the investment case for Latin American retailer FEMSA (Fomento Económico Mexicano).
In our final podcast episode of 2025, our sector portfolio managers are tasked with sharing their highest-conviction ideas for the year ahead.
Alison Savas is joined by Portfolio Manager Vihari Ross to unpack what’s driving US resilience, from fiscal scaffolding supporting consumption to the AI investment boom reshaping corporate earnings.
In this podcast, Alison Savas and Ian Harnett discuss the global macro outlook, equity valuations, AI market concentration, and tariff risks for investors.
In this episode, Alison Savas is joined by Pinnacle Investment Management Group’s Chief Investment Strategist, Anthony Doyle.
In this episode of the Good Value podcast, Investment Director, Alison Savas interviews Portfolio Manager, Graham Hay.

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X